|
Name |
Arisugacin C
|
Molecular Formula | C27H32O6 | |
IUPAC Name* |
(1R,2R,7S,10R)-7-hydroxy-14-(4-methoxyphenyl)-2,6,6,10-tetramethyl-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-12(17),13-diene-5,16-dione
|
|
SMILES |
C[C@]12CCC(=O)C([C@@]1(CC[C@@]3([C@@H]2CC4=C(O3)C=C(OC4=O)C5=CC=C(C=C5)OC)C)O)(C)C
|
|
InChI |
InChI=1S/C27H32O6/c1-24(2)22(28)10-11-25(3)21-14-18-20(33-26(21,4)12-13-27(24,25)30)15-19(32-23(18)29)16-6-8-17(31-5)9-7-16/h6-9,15,21,30H,10-14H2,1-5H3/t21-,25-,26-,27-/m1/s1
|
|
InChIKey |
XKDGQMPLQPRTCS-HHPVDLARSA-N
|
|
Synonyms |
Arisugacin C; CHEMBL3632852; (4aS,6aR,12aR,12bR)-4a-hydroxy-9-(4-methoxyphenyl)-4,4,6a,12b-tetramethyl-1,4a,5,6,6a,12,12a,12b-octahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,11(4H)-dione; CHEBI:65437; BDBM50130210; Q27133882; (1R,2R,7S,10R)-7-hydroxy-14-(4-methoxyphenyl)-2,6,6,10-tetramethyl-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-12(17),13-diene-5,16-dione
|
|
CAS | NA | |
PubChem CID | 10503812 | |
ChEMBL ID | CHEMBL3632852 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 452.5 | ALogp: | 3.7 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 82.1 | Aromatic Rings: | 5 |
Heavy Atoms: | 33 | QED Weighted: | 0.688 |
Caco-2 Permeability: | -4.775 | MDCK Permeability: | 0.00002050 |
Pgp-inhibitor: | 0.985 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.069 |
30% Bioavailability (F30%): | 0.954 |
Blood-Brain-Barrier Penetration (BBB): | 0.353 | Plasma Protein Binding (PPB): | 91.16% |
Volume Distribution (VD): | 0.653 | Fu: | 7.01% |
CYP1A2-inhibitor: | 0.526 | CYP1A2-substrate: | 0.926 |
CYP2C19-inhibitor: | 0.786 | CYP2C19-substrate: | 0.802 |
CYP2C9-inhibitor: | 0.779 | CYP2C9-substrate: | 0.848 |
CYP2D6-inhibitor: | 0.333 | CYP2D6-substrate: | 0.895 |
CYP3A4-inhibitor: | 0.865 | CYP3A4-substrate: | 0.522 |
Clearance (CL): | 6.782 | Half-life (T1/2): | 0.336 |
hERG Blockers: | 0.597 | Human Hepatotoxicity (H-HT): | 0.66 |
Drug-inuced Liver Injury (DILI): | 0.671 | AMES Toxicity: | 0.014 |
Rat Oral Acute Toxicity: | 0.602 | Maximum Recommended Daily Dose: | 0.904 |
Skin Sensitization: | 0.07 | Carcinogencity: | 0.713 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.943 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003231 | 0.752 | D06XZW | 0.273 | ||||
ENC003130 | 0.731 | D0P1UX | 0.267 | ||||
ENC003232 | 0.632 | D0J1ML | 0.258 | ||||
ENC005020 | 0.452 | D0N0RU | 0.258 | ||||
ENC002118 | 0.443 | D06HBQ | 0.252 | ||||
ENC002192 | 0.442 | D0V4WD | 0.250 | ||||
ENC000932 | 0.415 | D09WKB | 0.250 | ||||
ENC002044 | 0.406 | D03SKD | 0.248 | ||||
ENC002102 | 0.393 | D02DPU | 0.248 | ||||
ENC003422 | 0.390 | D04UTT | 0.243 |